The Mempel laboratory in the Center for Immunology and Inflammatory Diseases (CIID) at Massachusetts General Hospital and Harvard Medical School is seeking a highly motivated postdoctoral fellow to study the epigenetic control of regulatory T cell (Treg) stability in tumor tissue. Our lab’s recent findings indicate that inhibition of the CARMA1-BCL10-MALT1 pathway destabilizes Treg and selectively in the tumor microenvironment reprograms these cells into anti-tumor effector cells that express pro-inflammatory cytokines. (Di Pilato M et al, Nature, 2019). We are seeking a PhD or MD/PhD scientist with a background in genomics approaches (e.g. ChIP-seq, bisulfite-seq etc.) and an interest in T cell biology and tumor immunology to lead follow-up studies to identify the environmental triggers and molecular mechanisms of Treg instability and pro-inflammatory gene expression. The goal of these studies is to discover novel approaches for cancer immunotherapy.
The ideal candidate has a strong background and experimental expertise in cellular and molecular immunology, including in genomics approaches and in in vivo mouse studies. Both national and international candidates are encouraged to apply, but a documented track record of significant prior scientific achievement in the field of immunology or closely related disciplines is required.
Applicants should submit 1. a cover letter describing their previous scientific accomplishments and interests and career goals, 2. their C.V. and 3. contact information for three references via e-mail to Thorsten Mempel, MD, PhD: firstname.lastname@example.org